Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study

Selective inhibition of tyrosine kinase 2 (TYK2) may offer therapeutic promise in inflammatory conditions, with its role in downstream pro‐inflammatory cytokine signaling. In this first‐in‐human study, we evaluated the safety, tolerability, and pharmacokinetics (PK) of a novel TYK2 inhibitor, PF‐068...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Transl Sci
Main Authors: Singh, Ravi Shankar P., Pradhan, Vivek, Roberts, Erika S., Scaramozza, Matthew, Kieras, Elizabeth, Gale, Jeremy D., Peeva, Elena, Vincent, Michael S., Banerjee, Anindita, Fensome, Andrew, Dowty, Martin E., Winkle, Peter, Tehlirian, Christopher
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7993274/
https://ncbi.nlm.nih.gov/pubmed/33290616
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12929
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados